RxDoctor Payments Data

Fatin Qazait, NP

Family · Dickson, TNNPI 1255760971

Payments from drug & device makers

$1,334in general payments, 2019–2025

Across 73 payments — averaging $18.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$243
  • Novartis$197
  • Boehringer Ingelheim$193
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$139
  • Johnson & Johnson$122
  • Abbott$80
  • plus $360 from 9 others

What the payments were for

  • Food & beverage$1,334100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,334 in reported general payments places this provider in the 70th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$93,305
Medicare patients
477
Services billed
1,152

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban167$194,920
JardianceEmpagliflozin23$28,348
XareltoRivaroxaban24$26,310
EntrestoSacubitril/Valsartan17$24,816
Repatha SureclickEvolocumab15$18,238
FarxigaDapagliflozin Propanediol23$16,584
Metoprolol Succinate465$4,854
Ranolazine ErRanolazine44$4,818
Atorvastatin Calcium213$2,785
Amiodarone Hcl45$2,639
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide113$2,133
Losartan Potassium251$2,036
Prasugrel Hcl21$1,818
Rosuvastatin Calcium117$1,493
Spironolactone144$1,225

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$66$194,920167 claims
Boehringer IngelheimJardiance$193$28,34823 claims
Johnson & JohnsonXarelto$122$26,31024 claims
NovartisEntresto$197$24,81617 claims
AstraZenecaFarxiga$12$16,58423 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 6,706 family providers in Tennessee.

Other family in Dickson

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →